Prostate Cell News Volume 9.00 | Jan 5 2018

TOP STORY

PrLZ Increases Prostate Cancer Docetaxel Resistance by Inhibiting LKB1/AMPK-Mediated Autophagy

Researchers investigated the role of prostate leucine zipper (PrLZ) in docetaxel resistance in prostate cancer (PCa), focusing on PrLZ-regulating autophagy pathway. Human PCa PC3, LNCaP and C4-2 cell lines were used as the model system in vitro and PCa xenografts and PrLZ-knockout mice were used as the model system in vivo. [Theranostics] Full Article

(Ranked by impact factor of the journal)

Histone Methyltransferase KMT2D Sustains Prostate Carcinogenesis and Metastasis via Epigenetically Activating LIFR and KLF4

Investigators profiled the mutational spectrum of 32 significantly prostate cancer-associated genes by using disease-targeted sequencing, and found that KMT2D was highly mutated in Chinese patients. [Oncogene] Full Article

DBC1 Promotes Castration-Resistant Prostate Cancer by Positively Regulating DNA Binding and Stability of AR-V7

The authors report DBC1 as a key regulator of AR-V7 transcriptional activity and stability in castration-resistant prostate cancer (CRPC) cells. DBC1 functioned as a coactivator for AR-V7 and was required for the expression of AR-V7 target genes including CDH2, a mesenchymal marker linked to CRPC progression. [Oncogene] Abstract

Histone 2B-GFP Label-Retaining Prostate Luminal Cells Possess Progenitor Cell Properties and Are Intrinsically Resistant to Castration

Using a bigenic mouse model to earmark, isolate, and characterize quiescent stem-like cells, researchers identified a label-retaining cell (LRC) population in the luminal cell layer as luminal progenitors. Molecular and biological characterizations showed that these luminal LRCs are significantly enriched in the mouse proximal prostate, exhibit relative dormancy, display bipotency in both in vitro and in vivo assays, and express a stem/progenitor gene signature with resemblance to aggressive prostate cancer. [Stem Cell Reports] Full Article | Press Release | Graphical Abstract

Enzalutamide and CXCR7 inhibitor Combination Treatment Suppresses Cell Growth and Angiogenic Signaling in Castration-Resistant Prostate Cancer Models

Investigators showed that CXCR7 expression is upregulated in VCaP and C4-2B cells after enzalutamide treatment. [Int J Cancer] Abstract

Extracellular Vesicles as Drivers of Epithelial-Mesenchymal Transition and Carcinogenic Characteristics in Normal Prostate Cells

To evaluate the role of extracellular vesicles (EVs) in the cellular microenvironment, scientists have treated the normal epithelial prostate cell lines, RWPE-1 and PNT-2, with a pool of EVs from biopsies of prostate primary tumors, biopsies of benign prostate hyperplasia, plasma of prostate cancer patients or plasma of healthy individuals. [Mol Carcinog] Abstract

The Triterpenoid Corosolic Acid Blocks Transformation and Epigenetically Reactivates Nrf2 in TRAMP-C1 Prostate Cells

Researchers investigated the effect of corosolic acid on cellular transformation and the reactivation of nuclear factor erythroid 2-related factor 2 (Nrf2) through epigenetic regulation in TRAMP-C1 prostate cells. [Mol Carcinog] Abstract

The Expression of AURKA Is Androgen Regulated in Castration-Resistant Prostate Cancer

Scientists provided further evidence that Aurora kinase A (AURKA) is significantly overexpressed in androgen receptor (AR)-positive castration-resistant prostate cancer samples carrying amplification of AR gene and/or expressing AR in high levels. They also demonstrated androgen-induced AR binding in the intronic region of AURKA. [Sci Rep] Full Article

The Inhibitory Effects of Capillarisin on Cell Proliferation and Invasion of Prostate Carcinoma Cells

Researchers evaluated the potential actions of capillarisin (Cap) on the cell proliferation, migration and invasion of prostate carcinoma cells. Cap inhibited androgen-independent DU145 and androgen-dependent LNCaP cell growth through the induction of cell cycle arrest at the G0/G1 phase by upregulating p21 and p27 while downregulating expression of cyclin D1, cyclin A and cyclin B. [Cell Prolif] Abstract

Extracellular Vesicles in the Adaptive Process of Prostate Cancer during Inhibition of Androgen Receptor Signaling by Enzalutamide

Investigators report the effects of androgen receptor antagonist, enzalutamide on the protein contents of extracellular vesicles (EVs). EVs mediate cell-to-cell communication and increasing evidence shows the role of EVs in promoting cancer survival and metastasis. [Proteomics] Abstract

The Molecular Biology of Prostate Cancer: Current Understanding and Clinical Implications

With continuous progress over the past few decades in understanding diagnosis, treatment, and genetics, much has been learned about the prostate cancer-diagnosed genome. [Prostate Cancer Prostatic Dis] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

$1M Grant Supports Rutgers Cancer Institute of New Jersey Researcher on International Prostate Cancer Study

A $1 million grant from Gateway for Cancer Research will help Rutgers Cancer Institute of New Jersey Urologic Oncology Chief Isaac Yi Kim, MD, PhD, MBA evaluate the impact of surgically removing the prostate in men with metastatic prostate cancer in the United States and Asia. [Rutgers Cancer Institute] Press Release

PCM-075, Trovagene’s Polo-Like Kinase 1 (PLK1) Inhibitor Enhances Activity of Abiraterone in mCRPC Tumor Cells and May Represent a Novel Combination Treatment Option in mCRPC

Trovagene, Inc. announced the filing of its protocol for a Phase II clinical trial of PCM-075 in combination with abiraterone acetate, for metastatic castration-resistant prostate cancer (mCRPC) has been submitted to the FDA for review. [Trovagene, Inc.] Press Release

U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer

Janssen Biotech, Inc. announced that the FDA has granted Priority Review designation for the New Drug Application for apalutamide, an investigational, next-generation oral androgen receptor inhibitor for the treatment of men with non-metastatic castration-resistant prostate cancer. [Janssen Biotech, Inc.] Press Release

Germany vs Elsevier: Universities Win Temporary Journal Access after Refusing to Pay Fees

The Dutch publishing giant Elsevier has granted uninterrupted access to its paywalled journals for researchers at around 200 German universities and research institutes that had refused to renew their individual subscriptions at the end of 2017. [Nature News] Editorial

New NCI Director Expects Big Data to Revolutionize Cancer Research, Care

Cancer researchers were nervous about who President Donald Trump would choose to replace Harold Varmus as director of the National Cancer Institute (NCI). But their fears of an unconventional candidate proved unfounded when he tapped Norman “Ned” Sharpless. Sharpless, 51, who was then director of the Lineberger Comprehensive Cancer Center at the University of North Carolina in Chapel Hill. [ScienceInsider] Editorial

Nobel Laureate Will Step Down from Leading Embattled Salk Institute

Elizabeth Blackburn, the Nobel Prize–winning molecular biologist who took over just two years ago as president of the Salk Institute for Biological Studies in San Diego, California, announced her intent to retire this summer. The unexpected news comes as Salk faces gender discrimination lawsuits from three veteran female scientists and Blackburn herself has been challenged for not moving quickly enough to change what one plaintiff’s suit called an “old boys club” at the renowned research institute. [ScienceInsider] Editorial

NEW Gordon Research Conferences: Fibroblast Growth Factors in Development and Disease
March 25-30, 2018
Ventura, California, United States

Visit our events page to see a complete list of events in the community.

NEW Assistant Professor, Associate Professor & Professor – Cell & Molecular Biology (University of Mississippi)

NEW Postdoctoral Positions – Gene Regulation and/or Cancer Biology (University of North Carolina)

Postdoctoral Scientist – Prostate Oncobiology (CRUK Manchester Institute)

Assistant/Associate Professor – Prostate Cancer (Northwestern University)

Postdoctoral Fellowship – Prostate Cancer (Duke University Medical Center)

PhD Studentship – Prostate Cancer (CRUK Manchester Institute)

Postdoctoral Positions – Cancer Biology (University of Pennsylvania)

Assistant Professor – Prostate Cancer (University of Illinois)

Postdoctoral Position – Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Prostate Related Diseases (Baylor College of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.